Health benefits of intensive blood pressure control outweigh a slight risk of developing kidney disease
A new study found that in people who do not have chronic kidney disease (CKD), an intensive blood pressure control regimen increases risk of declining kidney function; this risk is generally outweighed by a reduced risk for cardiovascular events and death.
ConclusionsSpecialist and PCP visit in the immediate post-discharge period may improve 90-day HF readmission and mortality in certain high-risk groups of patients with HF.
Authors: Li Q, Zhang A, Xing C, Yuan Y Abstract Chronic kidney disease (CKD) is recognized as a worldwide health problem. Progression of CKD may lead to many serious complications, which are associated with increased morbidity and mortality. Presently, there is no satisfactory treatment. Thus, targeted therapies are urgently needed. The kidneys are second to the heart in terms of mitochondrial abundance and oxygen consumption. Thus, it is not surprising that mitochondrial homeostasis is absolutely essential for the normal function of the kidney. In fact, a number of reports indicate that mitochondria are involved i...
Conclusion: Among adolescents in a nationally representative survey, hypernatremia and hyperosmolality were associated with high SBP and decreased eGFR. These findings may support the hypothesis that an imbalance of salt and water contribute to hypertension and CKD.Nephron
Publication date: Available online 19 March 2019Source: American Journal of Kidney DiseasesAuthor(s): Junichi Ishigami, William V. Padula, Morgan E. Grams, Alexander R. Chang, Bernard Jaar, Ron T. Gansevoort, John F.P. Bridges, Csaba P. Kovesdy, Shinichi Uchida, Josef Coresh, Kunihiro MatsushitaRationale &ObjectivePneumococcal vaccine is recommended for adults 65 years and older and those younger than 65 years with clinical indications (eg, diabetes, lung/heart disease, kidney failure, and nephrotic syndrome). Its cost-effectiveness in less severe chronic kidney disease (CKD) is uncharacterized.Study DesignCost-effecti...
Publication date: Available online 19 March 2019Source: American Journal of Kidney DiseasesAuthor(s): Elaine Ku, Benjamin J. Lee, Jenny Wei, Matthew R. WeirHypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nerv...
CONCLUSIONSurgeons should be aware of the persistent renal defects caused by long term lithium use and development of nephrogenic diabetes insipidus even years after medication cessation.
In patients with type 2 diabetes mellitus and cardiovascular disease, empagliflozin (EMPA) decreased progression of chronic kidney disease, likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel blockers and diuretics. Nonsteroidal anti-inflammatory drugs may also be used by some individuals.
Conclusions Large proportions of patients with chronic kidney disease received nephrotoxic drugs, mainly diuretics. However, patients aged 60 years or older, and those at chronic kidney disease stages 2–3 were significantly more likely to receive contraindicated nephrotoxic drugs compared to other age groups and chronic kidney disease stages.
ConclusionsA clinically relevant model of PTA of venous stenosis in mice was created. PTA-treated vessels had increased lumen vessel area and WSS. The alterations in tissue markers of vascular remodeling, tissue hypoxia, proliferation, and cell death may be implications for future design of drug and device development.
Conclusions: AKI and CKD led to increased systemic oxidative stress. AOPP and fructosamine could be considered potential biomarkers for both, acute and chronic kidney damage. On the other hand, AGEs, TAC, and FRAP seem to be disease specific, which could help to differentiate between acute and chronic kidney injuries. However, this needs further validation in clinical studies. PMID: 30886657 [PubMed - in process]